Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial

Table 2

Common adverse events during treatment.

Event	Docetaxel alone (n)	Gefitinib + docetaxel (n)
Diarrhoea	8	8
Nausea	8	5
Vomiting	5	3
Fatigue	8	9
Rash	4	6

n: number of patients experiencing adverse event.